ArticleEuropean thyroid journal2025
The relationship between levothyroxine dosage and free thyroxine levels in hypothyroid patients: a large retrospective study.
Article in European thyroid journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study examined the relationship between levothyroxine dosage and free thyroxine levels in hypothyroid patients. The aim was to ascertain whether elevated free thyroxine in treated patients suggests overmedication or is essential for maintaining appropriate free triiodothyronine levels, guiding improved monitoring practices during therapy. Methods: A retrospective analysis was conducted on 3,020 free thyroxine measurements from 1,409 patients between July 2021 and March 2024. Patients with thyrotropin receptor antibodies or treated with antithyroid drugs such as thiamazole, propylthiouracil, and potassium iodide were excluded. Measurements were performed using the Elecsys FT4 III immunoassay, and statistical comparisons were made between levothyroxine-treated and untreated groups. Results: Levothyroxine-treated patients showed significantly higher median free thyroxine levels (17.9 pmol/L, interquartile range (IQR): 15.6-20.1) than untreated patients (16.2 pmol/L, IQR: 14.5-17.9, P < 0.0001). In addition, the free triiodothyronine/free thyroxine ratio was significantly lower in levothyroxine-treated patients (0.24, IQR: 0.20-0.29) than in untreated patients (0.28, IQR: 0.25-0.32, P < 0.0001). Free thyroxine levels increased with levothyroxine dosage, whereas the free triiodothyronine/free thyroxine ratio decreased. Although thyroid-stimulating hormone levels did not differ significantly between the groups, higher levothyroxine doses were associated with mild suppression. Conclusion: The findings emphasize the importance of higher free thyroxine levels for maintaining adequate free triiodothyronine in levothyroxine-treated patients, underscoring the need to monitor free thyroxine, free triiodothyronine, and their ratio during therapy to optimize treatment outcomes. In addition, clinicians should recognize that higher levothyroxine doses may elevate free thyroxine levels beyond the reference range.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.